Other Information
−Removed: the fiscal quarter ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted
+Added: the fiscal quarter ended March 31, 2025, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted
or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are
defined in Item 408 of Regulation S-K).
−Removed: The information set forth
−Removed: in Part I, Item 2 in the first paragraph under the caption “ Recent Developments — Business — Intercompany
−Removed: Agreements with PAVmed ” is incorporated herein by reference.
−Removed: The information set forth in Part I, Item 2 under the caption “Recent Developments — Financing — March 2023 Senior Convertible
−Removed: Note Refinancing” is incorporated herein by reference.
exhibits filed as part of this Quarterly Report on Form 10-Q are set forth in the “ Exhibit Index ” below.
6 unchanged sentences
Incorporation
−Removed: Form of Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Preferred Stock.
−Removed: Certificate of Amendment to Certificate of Incorporation, dated July 23, 2024.
−Removed: Ninth Amendment to Management Services Agreement, dated as of August 6, 2024, by and between PAVmed Inc.
−Removed: and Lucid Diagnostics Inc.
+Added: Underwriting Agreement (April 2025 CMPO)
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
12 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.